Advanced Biomed Inc

Research Advanced Biomed Inc (ADVB) on Bullrun: valuation model: 53.5% overvalued, market cap USD 7.63M, P/E 29.3. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerADVB
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDiagnostics & Research
• CurrencyUSD
• Valuation signal53.5% overvalued
• Market capUSD 7.63M
• P/E29.3
• Financial periodFY2025
• Net income-USD 3.26M
• Free cash flow-USD 5.86M

Valuation Snapshot

Bullrun's latest valuation model marks Advanced Biomed Inc as 53.5% overvalued; latest market cap is USD 7.63M; P/E is 29.3.

About Advanced Biomed Inc

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device;

Frequently asked questions

Is Advanced Biomed Inc overvalued or undervalued?

Bullrun's valuation model currently marks Advanced Biomed Inc as 53.5% overvalued.

What is Advanced Biomed Inc's market cap?

Advanced Biomed Inc's market capitalization is USD 7.63M.

What is Advanced Biomed Inc's P/E ratio?

Advanced Biomed Inc's price-to-earnings (P/E) ratio is 29.3.

What does Advanced Biomed Inc do?

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan.